Genomic and phenotypic heterogeneity in prostate cancer

Michael C. Haffner, Wilbert Zwart, Martine P. Roudier, Lawrence D. True, William G. Nelson, Jonathan I. Epstein, Angelo M. De Marzo, Peter S. Nelson, Srinivasan Yegnasubramanian

Research output: Contribution to journalReview articlepeer-review

Abstract

From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous disease. Primary prostate cancers are often multifocal, having topographically and morphologically distinct tumour foci. Sequencing studies have revealed that individual tumour foci can arise as clonally distinct lesions with no shared driver gene alterations. This finding demonstrates that multiple genomically and phenotypically distinct primary prostate cancers can be present in an individual patient. Lethal metastatic prostate cancer seems to arise from a single clone in the primary tumour but can exhibit subclonal heterogeneity at the genomic, epigenetic and phenotypic levels. Collectively, this complex heterogeneous constellation of molecular alterations poses obstacles for the diagnosis and treatment of prostate cancer. However, advances in our understanding of intra-tumoural heterogeneity and the development of novel technologies will allow us to navigate these challenges, refine approaches for translational research and ultimately improve patient care.

Original languageEnglish (US)
Pages (from-to)79-92
Number of pages14
JournalNature Reviews Urology
Volume18
Issue number2
DOIs
StatePublished - Feb 2021

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Genomic and phenotypic heterogeneity in prostate cancer'. Together they form a unique fingerprint.

Cite this